# Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01431274** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 2624 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** tiotropium + olodaterol
- **DRUG:** tiotropium
- **DRUG:** olodaterol
- **DRUG:** tiotropium
- **DRUG:** tiotropium + olodaterol
- **DEVICE:** Respimat

## Key facts

- **NCT ID:** NCT01431274
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 2624 (ACTUAL)
- **Last updated:** 2015-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01431274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01431274, "Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01431274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*